Merck & Co (NYSE:MRK) is one of 133 companies within the Pharmaceuticals GICS industry group, which is in turn part of the 781 company GICS Health Care sector. MRK's market value is $150.5 billion which falls in the top 10% of its industry group. The stock's current Portfolio Grader ranking places it 120 among the 133 companies in this industry group, a position that is well below-average; squarely in the bottom quartile of the sector with a ranking of 679 among the 781 companies in the sector, and number 4,148 in the nearly 5,000 company Portfolio Grader universe.

Portfolio Grader currently ranks Merck & Co (NYSE:MRK) a Sell. The approach to investing incorporated in this analytical tool developed by Louis Navellier assesses and ranks nearly 5,000 stocks each week from a fundamental and quantitative perspective. MRK has maintained this ranking for the last month.

With a $152.9 billion market value, Merck & Co (NYSE:MRK) ranks in the top decile in its industry group, Pharmaceuticals, and in the top 10% of its sector group, Health Care, in market value. From the prospective of investment attractiveness, the stock's Portfolio Grader ranking currently places it 115 among the 133 companies in this industry group, a spot that is well below-average; squarely in the bottom quartile of the sector with a ranking of 674 among the 785 companies in the sector, and number 4,114 in the nearly 5,000 company Portfolio Grader universe.

Currently, Merck & Co (NYSE:MRK) has a Sell using Louis Navellier's investing methods and his Portfolio Grader stock evaluator. MRK has recently seen its Portfolio Grader rating downgraded over the last month from a Hold to a Sell.

Currently, Merck & Co (NYSE:MRK) has a Sell using Louis Navellier's investing methodology and his Portfolio Grader stock evaluator. MRK has recently seen its Portfolio Grader rating downgraded over the last month from a Hold to a Sell.

The current recommendation of Sell for Merck & Co (NYSE:MRK) has been derived by using the stock evaluator from Portfolio Grader, which incorporates Louis Navellier's investing methods. MRK has recently seen its Portfolio Grader rating downgraded over the last month from a Hold to a Sell.

Merck & Co (NYSE:MRK) is ranked as a Hold using Louis Navellier's Portfolio Grader stock evaluator, which incorporates his investing methodology. The current overall Portfolio Grader recommendation on the shares has changed twice in the past month, which represents a greater level of change than is typical.